EP Patent

EP0625513B1 — Mesomorphic compound, liquid crystal composition containing it, liquid crystal device using the composition, display apparatus and method

Assigned to Canon Inc · Expires 1999-09-22 · 27y expired

What this patent protects

Patent listed against Invokana.

Drugs covered by this patent

Invokana (CANAGLIFLOZIN) · Johnson & Johnson

Patent Metadata

Patent number: EP0625513B1
Jurisdiction: EP
Classification: —
Expires: 1999-09-22
Drug substance claim: No
Drug product claim: No
Assignee: Canon Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.